Pancreatic Cancer Research

ResearcherVA Greater Los Angeles Healthcare SystemActive in the last 2 years

Jacob S. Ankeny

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4595-8592; OpenAlex author ID A5034879140. Sources: OpenAlex.

Their work

Papers
8 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 8

  1. Age-Based Left-Digit Bias in the Treatment of Pancreatic Adenocarcinoma. Co-author DOI 10.1007/s12029-026-01459-1↗
  2. The association of new-onset diabetes with subsequent diagnosis of pancreatic cancer-novel use of a large administrative database. Co-author DOI 10.1093/pubmed/fdac118↗
  3. Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer. First author DOI 10.1245/s10434-017-6290-8↗
  4. Reality of Single Circulating Tumor Cell Sequencing for Molecular Diagnostics in Pancreatic Cancer. First author DOI 10.1016/j.jmoldx.2016.03.006↗
  5. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. Co-author DOI 10.1038/bjc.2016.121↗
  6. Improving pancreatic cancer diagnosis using circulating tumor cells: prospects for staging and single-cell analysis. First author DOI 10.1586/14737159.2015.1091311↗
  7. A mutated anti-CA19-9 scFv-Fc for positron emission tomography of human pancreatic cancer xenografts. Co-author DOI 10.1007/s11307-014-0733-4↗
  8. Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system. First author DOI 10.1245/s10434-013-3159-3↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eric Hans Jensen · 2 shared papers, 2023–2026 · strength 0.45
  2. Christopher James LaRocca · 2 shared papers, 2023–2026 · strength 0.45
  3. Schelomo Marmor · 2 shared papers, 2023–2026 · strength 0.45
  4. David G. Brauer · 1 shared paper, 2026 · strength 0.29
  5. Qianyun Luo · 1 shared paper, 2026 · strength 0.29
  6. James S. Tomlinson · 5 shared papers, 2013–2018 · strength 0.27
  7. Colin M. Court · 4 shared papers, 2015–2018 · strength 0.23
  8. Zev A. Wainberg · 4 shared papers, 2013–2018 · strength 0.20
  9. Matthew M. Rochefort · 4 shared papers, 2013–2016 · strength 0.18
  10. Mark D. Girgis MD · 3 shared papers, 2014–2018 · strength 0.16
  11. Keith M. Wirth · 1 shared paper, 2023 · strength 0.16
  12. Jason W. Denbo · 1 shared paper, 2023 · strength 0.16
  13. M J White · 1 shared paper, 2023 · strength 0.16
  14. Timothy R. Donahue · 2 shared papers, 2013–2016 · strength 0.08
  15. Howard A. Reber · 2 shared papers, 2013–2016 · strength 0.08
  16. Oscar Joe Hines · 2 shared papers, 2013–2016 · strength 0.08
  17. Anna M Wu · 1 shared paper, 2014 · strength 0.05
  18. James Steven Tomlinson · 1 shared paper, 2014 · strength 0.05
  19. Rabindra R. Watson · 1 shared paper, 2016 · strength 0.04
  20. V. Raman Muthusamy · 1 shared paper, 2016 · strength 0.04
  21. William H. Isacoff · 1 shared paper, 2013 · strength 0.03
  22. Graham W. Donald · 1 shared paper, 2013 · strength 0.03
  23. Brian E. Kadera · 1 shared paper, 2013 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.